University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

Mecker G. Möller, MD, discusses the importance of addressing gender biases in oncology.

A new center at the University of Chicago Medicine will tackle health inequities in cancer.

Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.

Daniel Olson, MD, discusses the significance of the FDA approval of lifileucel for patients with advanced melanoma.

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

Christine Bestvina, MD, discusses strategies for managing adverse effects associated with the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.

The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.

Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).

Peter Riedell, MD, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma.

The University of Chicago Medical Center ranks among the nation’s best hospitals in 10 specialties, according to results of the U.S. News & World Report’s annual survey.

Gregory W. Roloff, MD, discusses real-world outcomes from treatment with brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Faculty across 4 institutions discuss their participation in a 4-team initiative launched by Stand Up To Cancer® that focuses on expanding access to cancer care and research.

Sarah Ackroyd, MD, MPH, discusses the rationale and key results from a study of time-related treatment burden in patients receiving treatment for advanced, recurrent endometrial cancer.

Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.

Total ablation of all metastases in addition to standard systemic therapy did not improve progression-free survival or overall survival compared with standard systemic therapy alone in patients with oligometastatic breast cancer.

Walter M. Stadler, MD, discusses his role within the Stand Up To Cancer® 4-team initiative, where he will aim to enhance diversity in early-phase clinical trials in underserved urban community.

Andrzej Jakubowiak, MD, PhD, highlighted several key studies that influenced the development and design of the ATLAS trial, introduced conclusions from the initial efficacy data, and discussed how ongoing analysis could further contextualize and inform post-transplant treatment approaches in multiple myeloma.